• Ray Dirks
    Pluristem's New Data Proves Potency For Its Clinical Platform $PSTI http://seekingalpha.com/p/1jr6n
    1/21/14
    Reply (9)
    • muldoon1959: Can you give some insight into the price action today? For $PSTI longs it was quite contrary to what was expected, given the results.
      1/22/14
    • Robbster: Personally, I think the positive news was already built in to the price, it's had a nice run up to this news. Today was profit taking.
      1/22/14
    • Robbster: Think we'll see the upward trend resume now.
      1/22/14
    • muldoon1959: Robbster, I agree the safety aspects were probably priced, but the announcement went a good ways beyond safety, no?
      1/22/14
    • Robbster: The clinical included efficacy endpoints, so, assuming investors were familiar with the clinical design, those endpoints could be priced in.
      1/22/14
    • Robbster: Of course, the typical scenario is that clinical results have NOT been fully priced in, but in this case, seemed to be less of a mystery
      1/22/14
    • Robbster: OR could be something behind the scenes of which we have no knowledge <wry grin>. That would not be unusual in dev biotech land.
      1/22/14
    • muldoon1959: Yep. The story's just beginning on this.
      1/22/14
    • enigma_mttrrnd: hopefully $PSTI gets more coverage. From what I understand it not only met, but exceeded expectations in a few endpoints.
      1/22/14